Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy

References

• Nocturne G, Boudaoud S, Ly B, Pascaud J, Paoletti A, Mariette X. Impact of anti-TNF therapy on NK cells function and on immunosurveillance against B-cell lymphomas. J Autoimmun. 2017;80:56–64. doi:10.1016/j.jaut.2017.02.001
   PubMed Web of Science ®Google Scholar
• Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology. 2010;49(7):1215–1228. doi:10.1093/rheumatology/keq031
   PubMed Web of Science ®Google Scholar
• Catrina AI, Trollmo C, Klint E, et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum. 2005;52(1):61–72. doi:10.1002/art.20764
   Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. Inflamm Bowel Dis. 2007;13(11):1323–1332. doi:10.1002/ibd.20225
   PubMed Web of Science ®Google Scholar
• Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002;46(12):3151–3158. doi:10.1002/art.10679
   PubMed Web of Science ®Google Scholar
• Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17(1):212. doi:10.1186/s13075-015-0728-9
   PubMed Web of Science ®Google Scholar
• Zintzaras E. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165(20):2337–2344. doi:10.1001/archinte.165.20.2337
   PubMedGoogle Scholar
• Dassopoulos T, Sultan S, Falck–Ytter YT, Inadomi JM, Hanauer SB. American Gastroenterological Association Institute Technical Review on the Use of Thiopurines, Methotrexate, and Anti–TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn’s Disease. Gastroenterology. 2013;145(6):1464–1465. doi:10.1053/j.gastro.2013.10.046
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious Infection and Mortality in Patients With Crohnʼs Disease: more Than 5 Years of Follow-Up in the TREAT™ Registry. Am J Gastroenterol. 2012;107(9):1409–1422. doi:10.1038/ajg.2012.218
   PubMed Web of Science ®Google Scholar
• Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106(12):2146–2153. doi:10.1038/ajg.2011.283
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374(9701):1617–1625. doi:10.1016/S0140-6736(09)61302-7
   PubMed Web of Science ®Google Scholar
• Afif W, Sandborn WJ, Faubion WA, et al. Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2013;19(7):1384–1389. doi:10.1097/MIB.0b013e318281325e
   PubMed Web of Science ®Google Scholar
• Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and Biologics: A Quebec Claims Database Study. Inflamm Bowel Dis. 2015;21(8):1847–1853. doi:10.1097/MIB.0000000000000457
   PubMed Web of Science ®Google Scholar
• Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. JAMA. 2017;318(17):1679–1686. doi:10.1001/jama.2017.16071
   PubMed Web of Science ®Google Scholar
• D’Haens G, Reinisch W, Panaccione R, et al. Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn’s Disease With up to 6 Years of Follow-Up in the Pyramid Registry. Am J Gastroenterol. 2018;113(6):872–882. doi:10.1038/s41395-018-0098-4
   PubMed Web of Science ®Google Scholar
• Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108(1):99–105. doi:10.1038/ajg.2012.334
   PubMed Web of Science ®Google Scholar
• Yang C, Huang J, Huang X, et al. Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-tumour Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis. J Crohns Colitis. 2018;12(9):1042–1052. doi:10.1093/ecco-jcc/jjy065
   Web of Science ®Google Scholar
• Bernardes C, Russo P, Carvalho D, Saiote J, Ramos J. Lymphoproliferative Disorders in Inflammatory Bowel Disease Patients: is It the Drugs or the Disease. GE Port J Gastroenterol. 2018;25(4):175–178. doi:10.1159/000484440
   Google Scholar
• Ferraro S, Leonardi L, Convertino I, Blandizzi C, Tuccori M. Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies. Front Pharmacol. 2019;10:247. doi:10.3389/fphar.2019.00247
   Web of Science ®Google Scholar
• Biancone L, Armuzzi A, Scribano ML, et al. Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. J Crohns Colitis. 2016;10(8):913–924. doi:10.1093/ecco-jcc/jjw048
   Web of Science ®Google Scholar
• Haynes K, Beukelman T, Curtis JR, et al. Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum. 2013;65(1):48–58. doi:10.1002/art.37740
   PubMed Web of Science ®Google Scholar
• Beigel F, Steinborn A, Schnitzler F, et al. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf. 2014;23(7):735–744. doi:10.1002/pds.3621
   Web of Science ®Google Scholar
• Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311(23):2406–2413. doi:10.1001/jama.2014.5613
   PubMed Web of Science ®Google Scholar
• D’Haens G, Reinisch W, Colombel JF, et al. Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn’s Disease Treated With Infliximab [Remicade®] or Conventional Therapy. J Crohns Colitis. 2017;11(6):680–689. doi:10.1093/ecco-jcc/jjw221
   PubMed Web of Science ®Google Scholar
• Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(5):447–458. doi:10.1111/apt.12624
   PubMed Web of Science ®Google Scholar
• Osterman MT, Sandborn WJ, Colombel JF, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s disease. Gastroenterology. 2014;146(4):941–949. doi:10.1053/j.gastro.2013.12.025
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug Therapies and the Risk of Malignancy in Crohnʼs Disease: results From the TREAT™ Registry. Am J Gastroenterol. 2014;109(2):212–223. doi:10.1038/ajg.2013.441
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Uda A, Udagawa E, Hibi T. Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis. J Crohns Colitis. 2019. doi:10.1093/ecco-jcc/jjz204
   Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4(5):621–630. doi:10.1016/j.cgh.2006.03.002
   PubMed Web of Science ®Google Scholar
• Annese V, Beaugerie L, Egan L, et al. European Evidence-based Consensus: inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2015;9(11):945–965. doi:10.1093/ecco-jcc/jjv141
   PubMed Web of Science ®Google Scholar
• Jess T, Horváth-Puhó E, Fallingborg J, Rasmussen HH, Jacobsen BA. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol. 2013;108(12):1869–1876. doi:10.1038/ajg.2013.249
   PubMed Web of Science ®Google Scholar
• van den Heuvel TRA, Wintjens DSJ, Jeuring SFG, et al. Inflammatory bowel disease, cancer and medication: cancer risk in the Dutch population-based IBDSL cohort. Int J Cancer. 2016;139(6):1270–1280. doi:10.1002/ijc.30183
   Web of Science ®Google Scholar
• Reeson M, Ambrosio L, Lam G, et al. A148 EBV STATUS AND IMMUNOSUPPRESSANT USE IN IBD PATIENTS WHO SUBSEQUENTLY DEVELOP LYMPHOMA: A RETROSPECTIVE AND PROSPECTIVE STUDY. Journal of the Canadian Association of Gastroenterology. 2018;1(suppl_2):221–222. doi:10.1093/jcag/gwy009.148
   Google Scholar
• Shivaji UN, Sharratt CL, Thomas T, et al. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49(6):664–680. doi:10.1111/apt.15097
   PubMed Web of Science ®Google Scholar
• Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443–468. doi:10.1016/j.crohns.2013.12.013
   PubMed Web of Science ®Google Scholar
• Swoger JM, Regueiro M. Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops. Inflamm Bowel Dis. 2014;20(5):926–935. doi:10.1097/MIB.0000000000000002
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36–41.e1. doi:10.1016/j.cgh.2010.09.016
   PubMed Web of Science ®Google Scholar
• Click B, Regueiro M. Managing Risks with Biologics. Curr Gastroenterol Rep. 2019;21(1):1. doi:10.1007/s11894-019-0669-6
   Google Scholar
• Shah ED, Coburn ES, Nayyar A, Lee KJ, Koliani-Pace JL, Siegel CA. Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol Ther. 2020;51(5):527–533. doi:10.1111/apt.15637
   Web of Science ®Google Scholar
• Sebastian S, Neilaj S. Practical guidance for the management of inflammatory bowel disease in patients with cancer. Therap Adv Gastroenterol. 2019;12:1756284818817293. doi:10.1177/1756284818817293
   Web of Science ®Google Scholar
• Shelton E, Laharie D, Scott FI, et al. Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Gastroenterology. 2016;151(1):97–109.e4. doi:10.1053/j.gastro.2016.03.037
   PubMed Web of Science ®Google Scholar
• Axelrad J, Bernheim O, Colombel J-F, et al. Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. Clin Gastroenterol Hepatol. 2016;14(1):58–64. doi:10.1016/j.cgh.2015.07.037
   PubMed Web of Science ®Google Scholar
• Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and benefits of infliximab for the treatment of Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4(8):1017–1024. doi:10.1016/j.cgh.2006.05.020
   Web of Science ®Google Scholar
• Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn’s Disease: A Meta-Analysis. Clin Gastroenterol Hepatol. 2009;7(8):874–881. doi:10.1016/j.cgh.2009.01.004
   PubMed Web of Science ®Google Scholar